Esperion Therapeutics (ESPR) Long-Term Deferred Tax (2016 - 2017)

Esperion Therapeutics' Long-Term Deferred Tax history runs 2 years deep, the most recent figure standing at $99.8 million for Q4 2017.

• Quarterly Long-Term Deferred Tax rose 32.54% year-over-year to $99.8 million in Q4 2017, while the trailing twelve-month figure through Dec 2017 was $99.8 million (up 32.54% YoY) and the FY2017 annual result came in at $99.8 million, up 32.54% from the prior year.
• Long-Term Deferred Tax was $99.8 million for Q4 2017 at Esperion Therapeutics, up from $75.3 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $99.8 million in Q4 2017 and bottomed at $75.3 million in Q4 2016.